Biotage Extends Capabilities with Addition of PEG Resins for Solid Phase Peptide Synthesis

biotage_logo

Charlotte, North Carolina, U.S., November 30, 2010, / b3c newswire / – Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal chemistry, announced the addition of ChemMatrix® resins to its extensive offering of peptide synthesis and purification products. ChemMatrix is a patented 100% PEG resin from Matrix Innovation® that offers substantial advantages over traditional PS and PEG based resins for solid phase peptide synthesis.

 

“Biotage is a leader in the global development of tools and technology for peptide synthesis and purification. Earlier this year, we introduced the SyroWave® peptide synthesizer, more recently Resolux™ HPLC columns for peptides purification and now ChemMatrix resins.” says Scott Carr, VP of Commercial Operations. “Biotage truly delivers a total solution to professionals in this growing area of science.”

 

The ChemMatrix resin is a technological tool enabling synthesis of complex molecules from biological origin, peptides, oligionucleotides and small proteins typically used for therapeutic purposes. This resin is supplied as classical spherical beads, a tried and tested solution in the industry for almost 50 years but leverages today’s need for flexibility and exacting standards of quality and performance in the synthesis of especially difficult sequences.

 

There are many benefits to ChemMatrix, such as; exceptional stability, wide solvent compatibility, no leaching, optimum loading capacity allow users to achieve higher purities and yields of product, per gram of resin, especially in the case of difficult peptide sequences.

 

For more information regarding the complete line of Biotage products for peptide synthesis and purification, visit www.biotage.com/peptides.

 

 

About Biotage - www.biotage.com 
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. The customers include the world’s top pharma and biotech companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, and has offices in the United States, United Kingdom and Japan. Biotage has 245 employees and had sales of SEK 394,1m in 2009. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. 

 

 

For further press information at Biotage please contact:

Rob Thompson

Director of Marketing Communications

10430 Harris Oaks Blvd., Suite C

Charlotte, NC USA 28269

Tel: +1 704 654 4847

Fax: +1 704 654 4917

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.